Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport

被引:280
作者
Zhang, SH [1 ]
Morris, ME [1 ]
机构
[1] SUNY Buffalo, Dept Pharmaceut Sci, Sch Pharm & Pharmaceut Sci, Amherst, NY 14260 USA
关键词
D O I
10.1124/jpet.102.044412
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Flavonoids are constituents of fruits, vegetables, and plant-derived beverages, as well as components in herbal-containing dietary supplements. The objective of this investigation was to characterize the effect of flavonoids on P-glycoprotein (P-gp) mediated cellular efflux and to determine the molecular mechanism( s) of the flavonoid-drug interaction. Studies were conducted in the sensitive and multidrug resistant human breast cancer cell lines MCF-7 and MDA435/LCC6 and examined the effects of the flavonoids biochanin A, morin, phloretin, and silymarin on daunomycin (DNM) accumulation and doxorubicin cytotoxicity. The potential mechanism( s) involved in the interaction was evaluated by determining flavonoid effects on 1) P-gp ATPase activity, 2) [H-3] azidopine photoaffinity labeling of P-gp, and 3) cellular P-gp levels. The flavonoids increased [H-3] DNM accumulation in P-gp positive cells, but not P-gp negative cells, and these effects were both flavonoid concentration- and P-gp expression level-dependent. Biochanin A and silymarin potentiated doxorubicin cytotoxicity in P-gp positive cells. Biochanin A and phloretin stimulated, whereas morin and silymarin inhibited P-gp ATPase activity, confirming that these flavonoids interact with P-gp. Morin and silymarin significantly inhibited [H-3] azidopine photoaffinity labeling of P-gp, suggesting a direct interaction with P-gp substrate binding. A 24-h preincubation with all flavonoids, followed by flavonoid removal, did not alter cellular P-gp level in P-gp positive cells. In conclusion, biochanin A, morin, phloretin, and silymarin all inhibited P-gp-mediated cellular efflux and the mechanism of the interaction involved, at least in part, a direct interaction. The findings of this study indicate a potential for significant flavonoid-drug interactions with P-gp substrates.
引用
收藏
页码:1258 / 1267
页数:10
相关论文
共 41 条
[1]  
ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197
[2]   Modulation of liposomal membrane fluidity by flavonoids and isoflavonoids [J].
Arora, A ;
Byrem, TM ;
Nair, MG ;
Strasburg, GM .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) :102-109
[3]   Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein [J].
Benderra, Z ;
Trussardi, A ;
Morjani, H ;
Villa, AM ;
Doglia, SM ;
Manfait, M .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (03) :428-434
[4]   Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein [J].
Castro, AF ;
Altenberg, GA .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (01) :89-93
[5]  
Christensen JG, 1996, CANCER RES, V56, P574
[6]   OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
BHARDWAJ, G ;
GERLACH, JH ;
MACKIE, JE ;
GRANT, CE ;
ALMQUIST, KC ;
STEWART, AJ ;
KURZ, EU ;
DUNCAN, AMV ;
DEELEY, RG .
SCIENCE, 1992, 258 (5088) :1650-1654
[7]   Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein [J].
Conseil, G ;
Baubichon-Cortay, H ;
Dayan, G ;
Jault, JM ;
Barron, D ;
Di Pietro, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (17) :9831-9836
[8]   POTENTIATION OF ANTICANCER-DRUG CYTOTOXICITY BY MULTIDRUG-RESISTANCE CHEMOSENSITIZERS INVOLVES ALTERATIONS IN MEMBRANE FLUIDITY LEADING TO INCREASED MEMBRANE-PERMEABILITY [J].
DRORI, S ;
EYTAN, GD ;
ASSARAF, YG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 228 (03) :1020-1029
[9]   Use of complementary and alternative therapies in HIV-infected patients [J].
Duggan, J ;
Peterson, WS ;
Schutz, M ;
Khuder, S ;
Charkraborty, J .
AIDS PATIENT CARE AND STDS, 2001, 15 (03) :159-167
[10]   St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 [J].
Dürr, D ;
Stieger, B ;
Kullak-Ublick, GA ;
Rentsch, KM ;
Steinert, HC ;
Meier, PJ ;
Fattinger, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :598-604